Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review

Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline resectable PC, offering improved resection rates and enabling early intervention and patient sel...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 16; no. 9; p. 1632
Main Authors Endo, Yutaka, Kitago, Minoru, Kitagawa, Yuko
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 24.04.2024
Subjects
Adjuvant treatment
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical trials
Health aspects
Immunotherapy
Medical innovations
Medical prognosis
Medical research
Medicine, Experimental
Metastasis
Mortality
Oncology
Pancreatic cancer
Patients
Precision medicine
Review
Surgery
Survival
Tumors
pancreatic cancer
randomized controlled trials
neoadjuvant therapy
scoping review
Online AccessGet full text

Cover

More Information
Summary:Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline resectable PC, offering improved resection rates and enabling early intervention and patient selection. Several retrospective studies have validated its efficacy. However, previous studies have lacked intention-to-treat analyses and appropriate resectability classifications. Randomized comparative trials may help to enhance the clinical applicability of evidence. Therefore, after searching the MEDLINE database, this scoping review presents a comprehensive summary of the evidence from published (n = 14) and ongoing (n = 12) randomized Phase II and III trials. Diverse regimens and their outcomes were explored for both resectable and borderline resectable PC. While some trials have supported the efficacy of NAT, others have demonstrated no clear survival benefits for patients with resectable PC. The utility of NAT has been confirmed in patients with borderline resectable PC, but the optimal regimens remain debatable. Ongoing trials are investigating novel regimens, including immunotherapy, thereby highlighting the dynamic landscape of PC treatment. Studies should focus on biomarker identification, which may enable precision in oncology. Future endeavors aim to refine treatment strategies, guided by precision oncology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16091632